HomeCompareBRIBF vs JEPI

BRIBF vs JEPI: Dividend Comparison 2026

BRIBF yields 1062.70% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084463.97M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — BRIBF vs JEPI

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRIBF pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, BRIBF beats the other by $23,012,056,878,137.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + JEPI for your $10,000?

BRIBF: 50%JEPI: 50%
100% JEPI50/50100% BRIBF
Portfolio after 10yr
$16042232.01M
Annual income
$13,536,504,047,491.74/yr
Blended yield
84.38%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
JEPI buys
0
No recent congressional trades found for BRIBF or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFJEPI
Forward yield1062.70%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$32084464.00M$29.0K
Annual income after 10y$27,073,008,093,454.87$1,528.62
Total dividends collected$31704729.30M$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: BRIBF vs JEPI ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$116,970$106,269.93$11,260$840.19+$105.7KBRIBF
2$1,286,876$1,161,718.25$12,641$907.94+$1.27MBRIBF
3$13,321,776$11,944,818.28$14,150$978.20+$13.31MBRIBF
4$129,817,926$115,563,625.92$15,795$1,050.85+$129.80MBRIBF
5$1,191,375,681$1,052,470,500.56$17,584$1,125.74+$1191.36MBRIBF
6$10,301,704,979$9,026,933,000.21$19,526$1,202.74+$10301.69MBRIBF
7$83,971,400,363$72,948,576,035.34$21,628$1,281.69+$83971.38MBRIBF
8$645,568,504,677$555,719,106,288.88$23,898$1,362.43+$645568.48MBRIBF
9$4,683,603,649,023$3,992,845,349,018.69$26,347$1,444.79+$4683603.62MBRIBF
10$32,084,463,997,910$27,073,008,093,454.87$28,982$1,528.62+$32084463.97MBRIBF

BRIBF vs JEPI: Complete Analysis 2026

BRIBFStock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this BRIBF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs OBRIBF vs KOBRIBF vs MAINBRIBF vs JEPQBRIBF vs XYLDBRIBF vs DIVOBRIBF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.